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Summary: Early after starting combination antiretroviral therapy low CD4 cell count is the dominant 
risk factor for developing Kaposi sarcoma. In contrast, detectable HIV-1 RNA viral load becomes an 
increasingly important risk factor several years after treatment start, independently of 
immunodeficiency.  
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Abstract 
Background. Kaposi sarcoma (KS) remains a frequent cancer in HIV-positive patients initiating 
combination antiretroviral therapy (cART). We examined incidence rates and risk factors for 
developing KS in different periods since starting cART in patients from European observational HIV-
cohorts. 
Methods. We included HIV-positive adults starting cART after 01/01/1996. We analyzed incidence 
rates and risk factors for developing KS up to 90, 180 days and one, two, five, and eight years after 
cART start and fitted univariable and multivariable Cox regression models.  
Results. We included 109,461 patients from 21 prospective clinical cohorts in Europe with 916 
incident KS cases. The incidence rate per 100,000 person-years was highest six months after starting 
cART (953, 95% CI 866-1,048) and declined to 82 (95% CI 68-100) after five to eight years. Using 
multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen and 
calendar year, low current CD4 cell counts increased the risk of developing KS throughout all 
observation periods after starting cART. Lack of viral control was not associated with the hazard of 
developing KS in the first year after cART initiation, but was over time since starting cART increasingly 
positively associated (p<0.001 for interaction). 
Conclusion. In patients who started cART both incidence and risk factors for KS change with time 
since starting cART. Whereas early after starting cART low CD4 cell count is the dominant risk factor, 
detectable HIV-1 RNA viral load becomes an increasingly important risk factor in patients who started 
cART several years ago, independently of immunodeficiency. 
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INTRODUCTION 
Kaposi sarcoma (KS) remains a frequent cancer in HIV-positive patients, including in patients who are 
receiving combination antiretroviral therapy (cART) [1–4]. Higher detection rates of KS and KS 
becoming evident in the context of the immune reconstitution inflammatory syndrome (IRIS) may 
contribute to the increased KS risk shortly after cART initiation [5]. Few studies have examined the 
incidence rate of KS in HIV-positive patients who have started cART some years ago. A recent analysis 
of a large US cohort of HIV-positive patients found that the incidence of KS was very high in the first 6 
months after cART initiation (1,342/100,000 person-years (pys)) but decreased substantially 
thereafter and stabilized at a rate of around 164/100,000 pys more than six months after starting 
cART [3].  
Infection with human herpresvirus-8 (HHV-8) is a necessary cause of KS [6]. HHV-8 seroprevalence is 
high among men having sex with men (MSM) and in the general population of some regions of sub-
Saharan Africa, including Southern Africa and East Africa [6]. Likewise, high rates of KS incidence 
among patients having started cART several years ago, have been found among MSM in Europe [2] 
and in Africa [7–9]. Immunodeficiency, as indicated by low CD4 cell counts, and failure to suppress 
HIV replication have also been identified as risk factors for developing KS in HIV-positive individuals 
on cART [2,5,10]. However, it is unclear at present whether these risk factors influence KS 
development similarly soon after starting cART and many years after starting cART. In particular, the 
determinants of KS among patients who started cART several years ago have not been well defined.  
The aim of the present study was to gain a better understanding of the factors that drive the 
incidence of KS among patients initiating cART. We analyzed data from a large collaboration of 
European HIV cohort studies, the Collaboration of Observational HIV Epidemiological Research 
Europe (COHERE) in EuroCoord [11,12] to examine KS incidence rates and risk factors for KS in 
different time periods after the start of cART, from 30-90 days to 5-8 years after starting cART. 
 at Fachbereichsbibliothek on A
ugust 18, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
4 
 
MATERIALS & METHODS 
COHERE in EuroCoord  
The COHERE in EuroCoord is a collaboration of 40 cohorts of HIV-infected patients across Europe, led 
by two data centers in Bordeaux and Copenhagen [13]. Twenty-nine cohorts provided data for the 
current project. Patients are followed-up every 3-6 months. Participating cohorts collect and transfer 
standardized data using the HIV Cohorts Data Exchange Protocol [14]. Data collected include socio-
demographic factors, CD4-cell counts, HIV-1 RNA viral load measurements, antiretroviral drugs, AIDS-
defining events and deaths. The dataset for this analysis was merged on 04/06/2014 and included 29 
cohorts with 306,482 patients. Cohorts adhere to local ethical requirements for observational 
research [13]. 
Inclusion Criteria and Definitions 
We included HIV-positive adults aged ≥16 years who enrolled and started cART after 01/01/1996, 
when cART became widely available in most parts of Europe. Combination antiretroviral therapy was 
defined as a regimen of at least three drugs from any class, including nucleoside reverse 
transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease 
inhibitors (PI). We excluded patients with previous ART exposure to mono- or dual therapy. Patients 
with ≤30 days follow-up and prevalent KS cases diagnosed before or during the first 30 days after 
cART start were excluded from the analyses. We also excluded patients with missing information for 
gender, country or region of birth, date of birth; and cohorts with <100 eligible patients. 
We defined baseline CD4 cell count as the measurement closest to the start of cART with a time 
window of -90/+30 days. Baseline HIV-1 RNA viral load was the measurement closest to start cART 
with a time window of -90/+7 days. Suppression of HIV-1 replication was defined as HIV-1 RNA ≤500 
copies/mL. Late presenters were defined as CD4 cell count <350 cells/μl or CDC stage C at enrolment 
[15]. First-line regimens were classified as NNRTI-based, boosted PI-based, unboosted PI-based, or 
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other. Sex and exposure groups were defined as MSM, heterosexual men, and heterosexual women. 
Origin, i.e. country or region of birth, was categorized as European, African or other.  
Statistical Analysis 
Observation started 30 days after initiating cART. We used an intention-to-continue-treatment 
approach ignoring subsequent treatment changes and interruptions. We split observation time in six 
periods: 30-90 days, 91-180 days, 181 days-12 months, 1-2 years, 2-5 years and 5-8 years. The same 
patient could contribute time to several periods. Observation ended at the earliest of KS diagnosis, 
last follow-up visit, death or eight years after cART start. We calculated KS incidence rates by dividing 
the number of patients developing KS by the number of pys at risk and Poisson 95% confidence 
intervals (CI). We fitted Cox models separately for each of the six periods, including exposure group, 
origin, first-line regimen, calendar year of enrolment (four categories) and the time-updated 
(current) variables CD4 cell count (six categories), HIV-1 RNA (four categories) and age (four 
categories) into the models. We used the likelihood ratio test to test whether HRs changed across 
time periods (test for interaction between period and risk factor).  
In additional analyses we included baseline CD4 cell count or late presentation in the model, included 
square-root transformed CD4 cell counts and log-transformed HIV-1 RNA viral loads as continuous 
variables, and excluded the first six months after starting cART or patients enrolled into cohort 
before 2000. All analyses were done in Stata Version 13 (Stata Corporation, College Station, Texas, 
USA). Results are presented as medians with interquartile ranges (IQR), incidence rates per 100,000 
pys, crude and adjusted hazard ratios (HRs), with 95% CI.  
RESULTS  
Study Population 
A total of 109,461 patients from 21 cohorts from 10 European countries (Austria, Belgium, Denmark, 
Germany, France, Italy, Spain, Greece, The Netherlands, Switzerland) or the EuroSIDA study [16] 
were eligible for the current analyses. Supplemental Figure S1 shows the number of included and 
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excluded patients. The main reasons for excluding patients were enrolment before 1996 (52,717; 
27%), patients not starting cART (63,708; 32%), and patients not ART naïve at cART start (34,644; 
18%). A total of 9,347 KS cases were excluded. Of these 3,872 (41%) cases were diagnosed before 
1996. Of the cases diagnosed after 1996 3,414 (62%) were diagnosed within ≤30 days after cART 
initiation. Included and excluded patients were similar with respect to gender, age and CD4 cell 
counts at enrolment (data on file). Included patients had higher HIV-1 RNA viral loads at enrolment 
compared to excluded patients (median 75,000 copies/mL in included compared to 19,407 copies/mL 
in excluded patients). Patients who enrolled before 2000 were more likely to have missing HIV-1 RNA 
measurements and thus to be excluded from the multivariable analysis compared to patients who 
enrolled later.  
The baseline characteristics of the 109,461 included patients are shown in Table 1: 40,972 (37%) 
patients were MSM; 29,845 (27%) were women. The majority of patients (84,514; 77%) were of 
European origin; 16,330 (15%) were of African origin. Median age was 37.3 years (IQR 31.2-44.7 
years). The median CD4 cell count was 250 cells/µl (IQR 122-370 cells/µl), 15,652 (14%) patients were 
in CDC stage C. Median follow-up since starting cART was 4.6 years (IQR 2.0-8.7 years), total 
observation time 501,800 pys.  
A total of 916 patients developed KS after starting cART. Median time from starting cART to KS 
diagnosis was 223 days (IQR 77-987 days). KS patients were more likely to be male, MSM and 
enrolled during the early years of the cART era (1996-2000) than patients remaining free from KS 
(Table 1). Among 318 heterosexual men and women developing KS, 66% (211) were men and 34% 
(107) were women; 38% (124) were of African origin. Patients developing KS were often late 
presenters and started cART in a more advanced clinical stage than those not developing KS. Of the 
916 KS patients 705 had CD4 cell counts below 350, 106 between 350-500 and 105 above 500 cells/µl 
at KS diagnosis. Patients with >350 cells/µl at KS diagnosis were more likely to be MSM, to have 
higher age and higher CD4 cell counts at enrolment than patients with CD4 cell count <350 cells/µl at 
KS diagnosis. Median viral load at KS diagnosis was 358 copies/mL (IQR 0-27,750 copies/mL). Median 
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CD4 cell count was 243 cells/µl (IQR 107-409 cells/µl) and 450 cells/µl (IQR 280-596 cells/µl) in those 
developing KS 30-90 days and 5-8 years, respectively, after starting cART. Four hundred and eighteen 
(46%) KS cases were diagnosed during the first six months after starting cART; these patients had low 
baseline CD4 cell counts (median 85 cells/µl, IQR 27-230 cells/µl) and were often late presenters 
(340; 81%). 
Incidence Rates 
The overall KS incidence rate was 183/100,000 pys (95% CI 171-195). It was 1,472/100,000 pys in the 
period 30-90 days after starting cART, declined to 582/100,000 in period 91-180 days, to 
247/100,000 in period 181 days-1 year and to 120/100,000 in period 1-2 years after starting cART 
(Figure 1, panel A). The rate was similar in the subsequent two periods: about 82-85/100,000 pys 
beyond 2 years of starting cART. Panels B to F of Figure 1 show the incidence rate stratified by 
current CD4 cell count and HIV-1 RNA viral load, origin, exposure group and current age. For 
incidence rates per risk group and time period see supplement Table S1. In all periods after starting 
cART incidence rates were highest in patients with current CD4 cell counts <50 cells/µL, in patients 
with non-suppressed HIV-1 RNA viral replication, and in MSM. More than two years after starting 
cART, KS incidence in MSM was about 149-160/100,000 pys. The lowest rates were observed 5-8 
years after starting cART in women (23/100,000 pys), in patients with suppressed viral load 
(41/100,000) and in patients with CD4 cell counts >500 cells/µL (36/100,000 pys).  
Risk Factors by Period  
A total of 100,022 (91.4%) patients had complete data and were included in the multivariable 
analyses. The HRs from the multivariable Cox models by period after starting cART are shown in 
Table 2 and supplement Figure S2; results from univariable analyses are shown in supplement Table 
S2 and Table S3. The risk of KS was increased in MSM, in patients of African origin, and in patients 
with low current CD4 cell counts. The association was strongest for MSM (HR 5.87 comparing MSM 
with heterosexual men in period 30-90 days) and for current CD4 cell count (HR 7.37 comparing <50 
cells/µL with 350-499 cells/µL in period 30-90 days). There was little evidence for a difference in HRs 
 at Fachbereichsbibliothek on A
ugust 18, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
8 
across the six periods for exposure group, origin, calendar year of enrolment, first-line cART regimen 
or current CD4 cell count, with p values from tests of interaction between 0.12 and 0.93 (Table 2). 
The situation was different for current HIV-1 RNA viral load: there was no evidence of an association 
in the periods early after starting cART but an increasingly strong association emerged in the later 
periods (p<0.001). The HR comparing >100,000 copies/mL with <500 copies/mL was 3.08 (95% CI 
1.56-6.09) in period 1-2 years after starting cART and 9.72 (95% CI 5.34-17.7) 5-8 years after starting 
cART. In the overall multivariable analysis not stratified by time period (supplement Table S4) 
patients aged >50 years had a higher KS risk compared to patients aged ≤30 years. There was some 
evidence for an interaction between current age and time since starting cART (p=0.07). However, this 
finding was not robust in additional analyses (data on file). The baseline CD4 cell count (supplement 
Table S5) and late presentation (supplement Table S6) were associated with the risk of KS in the early 
periods after starting cART but not thereafter. Results were similar when including square-root 
transformed current CD4 cell counts and log-transformed HIV-RNA viral loads as continuous variables 
rather than categories of current CD4 count and HIV-1 RNA viral load (data on file). Tests for 
interaction for current CD4 and current HIV RNA were similar when we excluded the first 6 months 
after starting cART (p=0.413 and 0.004, respectively) and when we excluded patients enrolled before 
2000 (p=0.49 and <0.001, respectively). 
DISCUSSION  
In this collaborative analysis we found that the incidence rate of KS was around 1,500/100,000 pys in 
the first weeks after starting cART but declined thereafter to plateau at about 82-85/100,000 pys 
after two years since starting cART. In MSM the KS incidence rate was about 149-160/100,000 pys, 
even two years after starting cART. This is higher than the age-standardized incidence of the most 
frequent cancers in the general population (breast cancer 80/100,00 pys, prostate cancer 70/100,00 
pys [17]). Other patient groups with high KS incidence rates were migrants from sub-Saharan Africa, 
late presenters and patients with low CD4 cell counts. The lowest KS incidence rates were seen in 
heterosexual women who started cART several years ago. The strength of associations with KS in the 
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different periods tended to be similar for most risk factors with the exception of HIV-1 viral load. 
Viral load was not associated with KS up to one year after starting cART, but emerged as an 
increasingly important risk factor thereafter.  
Our analysis was based on a large European cohort collaboration including >100,000 patients and 
>500,000 pys of follow-up with longitudinal CD4 and HIV-1 RNA measurements and detailed 
information on origin, sexual orientation and drug regimens. This is one of few studies in patients 
who have started cART five years or longer ago [2,3] and to our best knowledge the first study to 
thoroughly examine changes in the importance of different risk factors over time since cART 
initiation, using time-updated values where appropriate. Our study has several limitations. Data on 
HHV-8 serostatus, KS stage, or KS-related IRIS were not available. For example, we could not assess 
whether the increased risk of KS during the first 6 months after cART initiation was related to IRIS [5]. 
The risk of unmasking IRIS is increased in patients with low CD4 cell nadir at cART initiation [18] and 
previous studies have shown that timely initiation of cART at high CD4 cell counts may reduce the 
risk of developing unmasking IRIS-KS [18–20].  
The most striking finding of our study is the emergence of HIV-1 RNA as an increasingly strong risk 
factor for KS in patients who had started cART several years ago. In this multivariable analysis the 
association between current HIV-1 RNA viral load and KS was independent of other risk factors, 
including immunodeficiency, and a dose-response relation was evident, with the highest risk of KS in 
those with viral loads >100,000 copies/mL. It therefore appears that early after starting cART the 
incidence of KS is largely driven by immunodeficiency whereas later on replicating HIV-1 and 
immunodeficiency independently contribute to the risk of KS. This might be explained by synergistic 
interactions between HIV and HHV-8 [21]. The HIV-1 Tat protein facilitates HHV-8 replication, which 
in turn may lead to an increased risk of KS [22,23]. Likewise, HHV-8 has been shown to activate HIV 
replication [24]. Our results indicate that consistent long-term suppression of HIV-1 RNA replication 
prevents such interactions and thus reduces the risk of KS. These findings suggest that monitoring 
viral load to detect treatment failures in a timely fashion might be important.  
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The KS incidence rates from this study are generally similar to estimates of previous studies [1–3] 
from Europe and the US (see supplement Table S7). Our study confirms that MSM have a higher risk 
of developing KS compared to heterosexual men [10,25–27], probably due to the higher 
seroprevalence of HHV-8 infection, whereas women are at lower risk of developing KS compared to 
men [10,27,7]. This and other studies have shown that Europeans have lower KS incidence rates 
compared to migrants from sub-Saharan Africa [10,28], which may again be explained by the higher 
HHV-8 seroprevalence in patients with African origins [6]. Previous studies have suggested that the 
risk of developing KS increases with age in patients who are not receiving cART [28] but not in 
patients who have started cART [2,3,28]. Our overall analysis not stratified by time period suggested 
an increased KS risk in patients aged > 50 years compared to patients aged ≤ 30 years. However, we 
did not observe a dose-response relationship and there was no robust evidence for an interaction 
with time since starting cART. In contrast to a recent study [29], our study did not show that boosted 
PI-based first-line regimens were associated with a lower risk of developing KS compared to NNRTI-
based regimens. We cannot exclude that confounding by indication may have influenced our 
findings. Moreover, we examined the initial first-line regimen only and adopted an intention-to-
continue-treatment approach, which ignored subsequent treatment changes and therefore limited 
our ability to detect associations of KS with different cART regimens. We found that low current CD4 
cell counts increased the risk of developing KS in each period after starting cART, whereas baseline 
CD4 cell count or late presentation predicted KS in the first months after cART initiation only. This 
finding is in line with a previous study which showed that low baseline CD4 cell counts were 
associated with an increased risk of developing KS in the first 6 months after starting cART but not 
thereafter [3].  
The risk of developing KS is particularly high in late presenters and patients with low current CD4 cell 
counts shortly after cART initiation. This observation might be explained by an increased vigilance of 
patients and physicians for signs of disease but also by unmasking IRIS–associated KS [20]. KS 
incidence and its associated risk factors in patients having started cART several years ago is not 
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completely understood. Our study confirms that low current CD4 cell count increases the risk of KS 
throughout all time periods after starting cART.  
In conclusion, this collaborative analysis of European HIV cohort studies shows that in patients 
starting cART both incidence and risk factors for KS change with treatment duration. Whereas early 
after starting cART immunodeficiency is the dominant risk factor, detectable HIV-1 RNA viral load 
becomes an increasingly important risk factor in patients who started cART several years ago, 
independently of immunodeficiency. Further research is needed on the interaction between HIV-1 
and HHV-8 replication and the risk of KS, and the potential impact of cART on HHV-8 viremia.  
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Table 1. Patient Characteristics at Start of Combination Antiretroviral Therapy. 
  
with KS without KS 
  N % N % 
Total 916   108,545   
Exposure group         
  MSM 554 60.5 40,418 37.2 
  Heterosexual contact 211 23.0 32,142 29.6 
  Women 107 11.7 29,738 27.4 
  Unknown 44 4.8 6,247 5.8 
Origin         
  Europe 713 77.8 83,801 77.2 
  Africa 146 15.9 16,184 14.9 
  North America 49 5.3 6,284 5.8 
  Other 8 0.9 2,276 2.1 
Age group [years]         
  Median (IQR) 38 (32.1-46.4) 37.3 (31.2-44.7) 
       16-30  152 16.6 22,256 20.5 
       31-40  366 40.0 43,238 39.8 
       41-50  233 25.4 27,903 25.7 
         >50  165 18.0 15,148 14.0 
CD4 cell count [cells/ul] 
     Median(IQR) 146 (43-302) 250 (124-370) 
 <50 224 24.5 12,278 11.3 
  50-99 105 11.5 8,104 7.5 
 100-199 155 16.9 17,120 15.8 
  200-349 188 20.5 31,793 29.3 
 350-499 87 9.5 16,592 15.3 
  ≥500 62 6.8 10,952 10.1 
 Missing 95 10.4 11,706 10.8 
HIV RNA viral load [copies/mL]     
 
Median(IQR) 147,819 (50,000-384,000) 75,000 (19,000-222,000) 
  ≥100,000 460 50.2 38,329 35.3 
 10,001-99,999 236 25.8 34,561 31.8 
  501-9,999 48 5.2 12,322 11.4 
 ≤500 3 0.3 1,561 1.4 
  Missing 169 18.4 21,772 20.1 
CDC stage 
      A/B 640 69.9 90,642 83.5 
 C 237 25.9 15,415 14.2 
  Missing 39 4.3 2,488 2.3 
Late Presentation  
      No 231 25.2 42,096 38.8 
 Yes 649 70.9 60,753 56.0 
  Missing 36 3.9 5,696 5.2 
First-line cART regimen 
     Nonboosted PI 253 27.6 21,478 19.8 
 
Boosted PI 334 36.5 37,918 34.9 
 NNRTI without PI 293 32.0 42,581 39.2 
 
Other 36 3.9 6,568 6.1 
Calendar year of enrolment     
 
 1996-2000  336 36.7 29,676 27.3 
   2001-2005  334 36.5 35,781 33.0 
  2006-2010  191 20.9 32,844 30.3 
   2011-2014 55 6.0 10,244 9.4 
Abbreviations: MSM, men who have sex with men; cART, combination antiretroviral therapy; KS, Kaposi 
Sarcoma; CDC, United States Centers for Disease Control; IQR, interquartile range; NRTI, nucleotide reverse-
transcriptase inhibitors; NNRTI, Non-nucleoside reverse-transcriptase inhibitors; PI, Protease inhibitors. 
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Table 2. Risk Factors for Developing Kaposi Sarcoma by Time Periods Since Starting Combination Antiretroviral Therapy. Results from Multivariable Cox Regression Models.# 
                     30-90 days 91-180 days 6 -12 months 1-2 years 2-5 years 5-8 years   
                     (201 KS/90789 patients) (130 KS/91646 patients) (116 KS/90511 patients) (93 KS/85735 patients) (156 KS/75503 patients) (94 KS/48498 patients)   
                     HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI p-value& 
Exposure 
group 
MSM 5.87 (3.90-8.83) 2.84 (1.84-4.39) 3.32 (2.05-5.37) 3.00 (1.78-5.05) 4.17 (2.73-6.35) 4.43 (2.55-7.70) 0.46 
Heterosexual men 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -   
Women 0.86 (0.50-1.48) 0.54 (0.30-0.96) 0.62 (0.33-1.16) 0.67 (0.34-1.30) 0.65 (0.37-1.13) 0.41 (0.18-0.95)   
Origin European 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 0.93 
African 2.01 (1.23-3.28) 2.07 (1.23-3.47) 2.22 (1.26-3.90) 2.21 (1.19-4.12) 1.96 (1.19-3.24) 1.69 (0.84-3.40)   
Other 0.86 (0.49-1.51) 1.53 (0.84-2.80) 0.67 (0.29-1.55) 1.22 (0.52-2.89) 1.02 (0.53-1.98) 0.65 (0.23-1.83)   
Age group 
[years]*  
16-30 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 0.07 
31-40 1.04 (0.67-1.64) 2.01 (1.05-3.85) 1.37 (0.75-2.50) 1.31 (0.62-2.74) 0.92 (0.54-1.59) 0.56 (0.27-1.17)   
41-50 1.34 (0.85-2.13) 1.70 (0.85-3.39) 1.08 (0.56-2.08) 1.65 (0.77-3.52) 0.83 (0.47-1.48) 0.28 (0.13-0.62)   
>50 1.52 (0.92-2.51) 2.74 (1.35-5.58) 1.90 (0.97-3.73) 2.42 (1.09-5.40) 1.21 (0.66-2.22) 0.52 (0.23-1.16)   
CD4 cell count 
[cells/µl]* 
<50 7.37 (4.26-12.7) 7.56 (3.85-14.8) 14.10 (6.68-29.8) 9.15 (4.06-20.6) 6.41 (3.40-12.1) 7.08 (3.32-15.1) 0.50 
50-99 4.93 (2.77-8.80) 5.53 (2.86-10.7) 4.33 (1.90-9.88) 4.24 (1.79-10.0) 4.35 (2.18-8.68) 1.90 (0.62-5.86)   
100-199 3.46 (2.04-5.85) 2.89 (1.56-5.34) 4.16 (2.20-7.87) 1.43 (0.66-3.11) 2.32 (1.31-4.11) 3.24 (1.60-6.54)   
200-349 1.89 (1.13-3.14) 1.52 (0.83-2.77) 1.62 (0.84-3.12) 1.04 (0.53-2.05) 1.45 (0.89-2.36) 1.33 (0.68-2.59)   
350-499 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -   
> 500 0.40 (0.17-0.94) 0.76 (0.36-1.59) 1.05 (0.53-2.07) 0.91 (0.49-1.71) 0.62 (0.38-1.00) 0.59 (0.32-1.11)   
HIV RNA viral 
loads 
[copies/mL]* 
≥100,000 1.46 (0.96-2.20) 1.65 (0.99-2.75) 1.81 (0.96-3.41) 3.08 (1.56-6.09) 5.34 (3.20-8.92) 9.72 (5.34-17.7) <0.001 
10,001-99,999 1.04 (0.65-1.68) 0.70 (0.34-1.43) 1.51 (0.77-2.96) 2.10 (1.07-4.12) 3.90 (2.46-6.19) 2.24 (1.11-4.53)   
501-9,999 1.28 (0.87-1.88) 1.04 (0.65-1.66) 1.46 (0.83-2.55) 0.95 (0.46-1.97) 2.24 (1.35-3.73) 2.25 (1.13-4.46)   
≤500 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -   
First-line cART 
regimen 
Nonboosted PI 0.53 (0.32-0.90) 0.82 (0.46-1.46) 1.65 (0.88-3.08) 0.86 (0.46-1.62) 0.95 (0.58-1.53) 0.91 (0.49-1.68) 0.12 
Boosted PI 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -   
NNRTI without PI 0.58 (0.42-0.81) 1.10 (0.72-1.69) 1.05 (0.66-1.65) 0.84 (0.50-1.41) 0.90 (0.60-1.36) 0.61 (0.32-1.14)   
Other 0.50 (0.22-1.15) 1.41 (0.70-2.86) 1.21 (0.50-2.90) - - 0.35 (0.13-0.99) 0.52 (0.18-1.54)   
Calendar year 
of enrolment 
1996-2000            1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 0.39 
2001-2005            1.20 (0.77-1.89) 0.79 (0.48-1.29) 1.84 (1.03-3.31) 0.60 (0.34-1.08) 1.23 (0.80-1.87) 0.99 (0.57-1.71)   
2006-2010            0.88 (0.53-1.44) 0.66 (0.38-1.18) 1.77 (0.91-3.43) 0.70 (0.37-1.33) 0.77 (0.42-1.41) 0.75 (0.17-3.34)   
2011-2014            1.29 (0.71-2.32) 1.01 (0.46-2.21) 1.46 (0.54-3.95) - - - - - -   
# Only cases with no missing values for any of the covariates have been used in this cox-regression model. Hazard ratios are adjusted for exposure group, origin, current age, current CD4 cell 
counts, current HIV RNA viral loads, first-line cART regimen, calendar period of enrolment; and stratified by cohort. Abbreviations: MSM, men who have sex with men; cART, combination 
antiretroviral therapy; KS, Kaposi Sarcoma; NNRTI, Non-nucleoside reverse-transcriptase inhibitors; PI, Protease inhibitors. * Time-updated data; & P-value for change over time from test of 
interaction     
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Figure 1: Kaposi Sarcoma Incidence Rates Overall and Stratified for Selected Risk Factors by Time 
Periods Since Starting Combination Antiretroviral Therapy. 
 
Abbreviations: cART, combination antiretroviral therapy; MSM, men who have sex with men; pys, 
person-years. 
 
 at Fachbereichsbibliothek on A
ugust 18, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
